On April 15th, LUMC Global and the LUMC’s Obstetrics and Gynecology department organized a very successful expert webinar Innovations in Fetal Therapy. We have published the entire recording of the event online!
If you did not attend the meeting and want to delve into the interesting content presented at the webinar or if you want to revisit some of the interesting presentations, check out the recording. The recording also includes Prof. Dick Oepkes‘ well deserved royal distinction. View the timetable in the description of the video to navigate easily through the recording!
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.
The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).